JAK2 and non-small cell lung carcinoma: Our findings showed that FXR-induced IL-6/IL-6ST/Jak2/STAT3 signaling promoted NSCLC metastasis, highlighting a novel therapeutic option for treating advanced or metastatic NSCLC.